FTC Issues Civil Investigative Demand to Johnson & Johnson Regarding Remicade

We have covered Pfizer’s antitrust suit against Johnson & Johnson, the manufacturer of REMICADE (infliximab), as well as a related antitrust litigation filed by retailers Walgreen and Kroger Co. and direct and indirect purchasers of Remicade.  The cases generally allege that Johnson & Johnson excluded Pfizer’s infliximab biosimilar from the market through anticompetitive bundling and rebate penalties for insurers and providers, causing inflated prices.  The FTC is now also investigating J&J’s contracting practices with respect to REMICADE.  In a recent SEC filing, J&J reported:  “In June 2019, the United States Federal Trade Commission (‘FTC’) issued a Civil Investigative Demand to Johnson & Johnson in connection with its investigation of whether Janssen’s REMICADE contracting practices violate federal antitrust laws.”

Stay tuned to Big Molecule Watch for further updates.

Download PDF